Clinical Trial Update: Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating lapatinib for recurrent or persistent endometrial cancer has completed with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Endometrial Carcinoma

Drugs mentioned

• Lapatinib (Lapatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Endometrial Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2015-09-18